Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus

Vibeke Strand
In: Current Opinion in Rheumatology · 1999 · vol. 11(5) , pp. 330–340 · doi:10.1097/00002281-199909000-00002 · PMID:10503651 · W1998135902
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

Systemic lupus erythematosus (SLE) is a difficult disease to study, having a variable disease course characterized by exacerbations and remissions. A variety of biologic agents are under investigation as potential treatments for SLE. These products are designed to specifically interfere with the following immunologic processes: T cell activation/T cell-B cell collaboration, production of anti-double-stranded DNA antibodies, deposition of anti-double-stranded DNA antibody complexes, complement activation, and immune complex deposition and cytokine activation and modulation. More aggressive interventions include gene therapy and stem cell transplantation. Immunomodulatory agents recently examined in patients with SLE include: thalidomide, AS101, 2' chlordeoxyadenosine, mycophenolate mofetil, and bindarit. Additional innovative pharmaceutical treatments include the mild androgen dehydroepiandrosterone, selective estrogen receptor modulators, and the prolactin inhibitor, bromocriptine. A variety of these biologic and pharmaceutical agents offer promise as potential therapies. Active participation in clinical trial efforts to develop international consensus regarding trial methodology and outcome measures are crucial to the development of these innovative therapies.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (48)

Source provenance

openalex
last seen: 2026-05-11T06:39:27.580236+00:00
unpaywall
last seen: 2026-08-20T06:30:07.000247+00:00
License: CC0 · commercial use OK